Search Results
210 Results Found for “migraine disorder”
Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...
Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...
In this narrative review, we aim to introduce the reader to the history of calcitonin gene-related peptide (CGRP) discovery and its involvement in migraine pathophysiology. We will then look at drug development and clinical trials in migraine. We will additionally ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
The 19th European Headache Congress (EHC25) was held in Lisbon and brought together headache specialists, researchers and healthcare professionals from across Europe and beyond. Under the theme Transforming challenges into solutions, the congress focused on translating advances in headache science into meaningful improvements in clinical care. The meeting addressed key challenges in the prevention, diagnosis and treatment of headache and facial pain disorders, with an emphasis on bridging basic science, translational research and real-world clinical practice.
In this year-end review, we are pleased to share personal highlights from members of the touchNEUROLOGY Editorial Board, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1Â Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
The 11th Congress of the European Academy of Neurology (EAN) delivered ground-breaking insights across neurology, showcasing how precision medicine is reshaping clinical practice. Taken from the EAN Highlights and Breaking news session presented 24 June 2025 (PLEN03), touchNEUROLOGY summarizes the key highlights across dementia, headache, movement disorders, cerebrovascular and neuromuscular diseases.
Prof. Simona Sacco discusses the evolving science behind anti-calcitonin gene-related peptide (CGRP) therapies for migraine and the promise of new delivery methods. Prof. Simona Sacco is a leading neurologist based at the University of L’Aquila, Italy, and currently serves as the President of the European Stroke Organisation (ESO). Her research spans migraine pathophysiology, stroke management, and health equity across Europe.
Rotterdam (ka). ‘Towards a better headache treatment for everyone’ - The ambitious motto of achieving better headache treatment for everyone was at the centre of the 18th European Headache Congress in Rotterdam. The top-class conference is regarded as an international platform for scientific exchange on the subject of headaches. Confidently chaired by Prof Antoinette Maassen van den Brink, Rotterdam and Prof Jan Versijpt, Brussels, the EHC 2024 Congress was a complete success with around 2,200 participants.
In our next expert Q&A we are delighted to welcome Dr Stewart Tepper. Dr Tepper, is a distinguished figure in the field of Neurology, currently serving as the Vice President of the New England Institute for Neurology and Headache (NEINH) in Stamford, Connecticut, and as a Professor of Neurology at the Geisel School of Medicine at Dartmouth.
In a new consensus statement, the American Headache Society recommends CGRP-targeting therapies as first-line options for migraine prevention, alongside existing treatments, without necessitating prior failure of other preventive treatments.
Data from the REFORM trial (NCT04674020) provide valuable insights into cortical inflammation in adults with migraines, using a novel quantitative, multimodal MRI technique to compare these patients with age- and gender-matched healthy controls, enhancing our understanding of migraine biology and other headache disorders. The discussion also covers cluster headaches, focusing on a study that examines premonitory symptoms in affected individuals and highlights key phenotypic characteristics. Additionally, we explore findings from the European Migraine & Headache Alliance on the stigma surrounding migraines, which yield insightful and actionable results. Looking ahead, the focus shifts to the latest data on new medications for preventing and treating migraine attacks, discussing future prospects and identifying areas in headache disorder management that still need further attention.
Case study Patient information A 42-year-old woman presented in the emergency department with acute onset whole-body myoclonic jerks for 1 day. On enquiry, the patient’s parents advised that she had a history of depression over the past 15 years. Intermittently, family ...
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a ...
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
